Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
| Period | Ended | Value | Kind | Source trail |
|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $1,396,611,000 | reported | |
| FY 2024 | 2024-12-31 | $1,015,324,000 | reported | |
| FY 2023 | 2023-12-31 | $829,253,000 | reported | |
| FY 2022 | 2022-12-31 | $660,116,000 | reported | |
| FY 2021 | 2021-12-31 | $443,310,000 | reported | |
| FY 2020 | 2020-12-31 | $267,594,000 | reported | |
| FY 2019 | 2019-12-31 | $195,992,000 | reported | |
| FY 2018 | 2018-12-31 | $151,862,000 | reported | |
| FY 2017 | 2017-12-31 | $316,613,000 | reported | |
| FY 2016 | 2016-12-31 | $146,691,000 | reported | |
| FY 2015 | 2015-12-31 | $135,057,000 | reported | |
| FY 2014 | 2014-12-31 | $75,334,000 | reported |
Halozyme Therapeutics, Inc. · CIK 1159036 · Engraved from SEC EDGAR
Twelve months to Sep 30, 2026 · derived
Halozyme Therapeutics, Inc. is the 8th largest of the 176 covered companies the SEC files under this code, by revenue. SIC 2836
Latest filing Nov 18, 2026
The us-gaap concepts with the most facts on file for this company.
Peers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.
| Fiscal year | Dividends | Buybacks | Total | Per share | Shares | Shares · yoy | of free cash flow |
|---|---|---|---|---|---|---|---|
| FY2025 | — | $342.37M | $342.37M | — | 118.02M sh | −4.2% | 53.1% |
| FY2024 | — | $250.00M | $250.00M | — | 123.15M sh | −2.9% | 53.4% |
| FY2023 | — | $402.38M | $402.38M | — | 126.82M sh | −6.3% |
| 107.8% |
| FY2022 | — | $200.00M | $200.00M | — | 135.37M sh | −1.7% | 85.0% |
| FY2021 | — | $350.06M | $350.06M | — | 137.70M sh | +1.8% | 117.5% |
776 managers · Quarter ended Sep 30, 2026All holders ›
160